FDA re­view de­tails sui­cides, car­dio risks linked to Valeant’s $100M drug bro­dalum­ab

At one point not long ago, As­traZeneca ex­ecs thought their IL-17 pso­ri­a­sis drug bro­dalum­ab could earn up to $1.5 bil­lion in an­nu­al sales. But af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.